BEIJING : A COVID-19 vaccine candidate currently undergoing early-stage human trials in China can produce a "robust" immune response against the novel coronavirus in mice and macaques, a new study says.The researchers, including those from Tsinghua University in China, noted that the vaccine candidate, called ARCoV, elicited both antibody as well as cell mediated immune response against the novel coronavirus SARS-CoV-2 in mice and non-human primates.According to the study, published in the journal Cell on Friday, ARCoV is currently being evaluated in phase I human trials to assess whether it is safe and generates an immune response in humans.ARCoV, which is an mRNA vaccine, is based on the genetic material of SARS-CoV-2, and enables host.